Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: A phase II study from the hoosier oncology group

Journal of Thoracic Oncology

Volumn 3, Issue 4, 2008, Pages 374-379

  Agarwala, Anuj ^a   Fisher, William ^b,c   Bruetman, Daniel ^b,d   McClean, John ^b,e   Taber, David ^b,f   Titzer, Michael ^b,g   Juliar, Beth ^a   Yu, Menggang ^a   Breen, Tim ^a   Einhorn, Lawrence H ^a,b   Hanna, Nasser ^a,b,g  

^a INDIANA UNIVERSITY   (United States)

^b Hoosier Oncology Group   (United States)

^c Medical Consultants   (United States)

^d Goshen Health System Center for Cancer Care   (United States)

^e Medical and Surgical Specialists LLC   (United States)

^f Northern Indiana Cancer Research Consortium   (United States)

^g Oncology Hematology Associates of SW Indiana ^*  (United States)

Author keywords

Celecoxib; Gefitinib; Non small cell lung cancer

Indexed keywords

CELECOXIB; DIURETIC AGENT; GEFITINIB;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ATELECTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DIARRHEA; DIZZINESS; DRUG WITHDRAWAL; DYSPNEA; FATALITY; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPOTENSION; INFECTION; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; LIVER DISEASE; LUNG ADENOCARCINOMA; LUNG INFILTRATE; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; PNEUMONIA; PRIORITY JOURNAL; RASH; SIDE EFFECT; SKIN DISEASE; SMOKING; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

EID: 41749124798     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181693869     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Non-small cell lung cancer collaborative group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899-909.
3. Souquest PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993;342:19-21.
4. Marino P, Pampallona S, Preatoni F, et al. Chemotherapy vs. Supportive care in advanced non-small cell lung cancer: results of a meta-analysis of the literature. Chest 1994;106:861-865.
5. Grilli R, Oxman A, Julian J. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 1993;11:1866-1872.
6. Stephens R, Fairlamb D, Gower N, et al. The Big Lung Trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting. Proc Am Soc Clin Oncol 2002;21:291a (abstract #1161).
7. Schiller J, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-98.
8. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 2003;21:2237-2246.
9. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell cancer: a randomized trial. JAMA 2003;290:2149-2158.
10. Sweeney C, Marshall M, Barnard D, et al. Cyclooxygenase 2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue. Cancer Detect Prev 2002;26:238-244.
11. Hida T, Kozaki K, Ito H, et al. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522 and conventional anti-cancer agents. Clin Cancer Res 2002;8:2443-2447.
12. Masferrer J, Leahy K, Koki A, et al. Antiangiogenic and antitumor activities of cyclooxygenase 2 inhibitors. Cancer Res 2000;60:1306-1311.
13. Qadri S, Wang J, Redmond K, et al. The role of COX-2 inhibitors in lung cancer. Ann Thorac Surg 2002;74:1648-1652.
14. Howe L, Subbaramaiah K, Patel J, et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 2002;62:5405-5407.
15. Niki T, Kohno T, Iba S, et al. Frequent co-localization of COX-2 and laminin-5gamma 2 chains at the invasive front of early-stage lung adenocarcinomas. Am J Pathol 2002;160:1129-1141.
16. Kinoshita T, Takahashi Y, Sakashita T, et al. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenase 1 and 2 in human colon carcinoma cells. Biochem Biophys Acta 1999;1438:120-130.
17. Coffey R, Hawkey C, Damstrup L, et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci 1997;94:657-662.
18. Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-1080.
19. Niho S, Kubota K, Goto K, et al. First-line single agent treatment with gefitinib in patients with advanced non-small cell lung cancer: a phase ii study. J Clin Oncol 2006;24:64-69.
20. Kris M, Sandler A, Miller V, et al. Cigarette smoking history predicts sensitivity to erlotinib: results of a phase II trial in patients with bronchioalveolar carcinoma (BAC). Proc Am Soc Clin Oncol 2004;22:631s (abstract #7062).
21. West H, Franklin W, Gumerlock P, et al. Gefitinib (ZD 1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study SO126. J Clin Oncol 2006;24:1807-1813.
22. Johnson B, Lucca J, Rabin M, et al. Preliminary results from a phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients >70 years of age with previously untreated advanced non-small cell lung carcinoma. Proc Am Soc Clin Oncol 2004;22:636s (abstract #7080).
23. Spigel D, Hainsworth J, Burkett E, et al. Single-agent gefitinib in patients with untreated advanced non-small cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network phase II trial. Clin Lung Cancer 2005;7:127-132.
24. Sandler A, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000;18:122-130.
25. Kelly K, Crowley J, Bunn P, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group Trial. J Clin Oncol 2001;19:3210-3218.
26. Gadgeel SM, Ruckdeschel JC, Heath EI, et al. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). J Thorac Oncol 2007;2:299-305.
27. O'Byrne KJ, Danson S, Dunlop D, et al. Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non-small cell lung cancer. J Clin Oncol 2007;25:3266-3273.
28. Fidler MJ, Argiris A, Patel JD, et al. Gastronintestinal hemorrhage in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib and celecoxib. J Clin Oncol 2006;20:7172. ASCO Meeting Abstracts.
29. Herbst R, Prager D, Hermann R, et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899.
30. Giaccone G, Herbst R, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT I. J Clin Oncol 2004;22:777-784.
31. Herbst R, Giaccone G, Schiller J, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004;22:785-794.
32. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-1552.
33. Csiki I, Morrow JD, Sandler A, et al. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celcoxib and docetaxel. Clin Cancer Res 2005;11:6634-6640.
34. Nugent FW, Mertens WC, Graziano S, et al. Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial. Cancer J 2005;11:209-216.
35. Gasparini G, Meo S, Comella G, et al. The combination of the selective cyclooygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates. J Thorac Cardiovasc Surg 2005;130:1406-1412.
36. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-139.
37. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
38. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients wish bronchioalveolar carcinoma subtypes: A Southwest Oncology Group Study. J Clin Oncol 2005;23:6838-6845.
39. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.